Arindam Basu

Dr. Basu
Assistant Professor, Biology
Office Phone
Office Location
Main Building, 312C
25 Yearsely Mill Rd
Media, PA 19063

Arindam Basu received his B.Sc. in Human Physiology at the University of Kolkata and his M.Sc. in Biotechnology from the Indian Institute of Technology, Bombay at Mumbai. He then did his Ph.D. at the Indian Institute of Science, Bangalore where he studied tissue-specific gene regulation and signal transduction. After completing his Ph.D., he joined the laboratory of Dr. Michael Atchison at the University of Pennsylvania to continue his research in the area of gene transcription and epigenetics. Before joining Penn State Brandywine he was promoted to Senior Research Investigator and was involved in investigating the role of YY1 in long range DNA interactions during B cell development and function. His current research interests are to understand the mechanism of recruitment of Polycomb Group (PcG) proteins to DNA and their epigenetic regulation of gene expression during different stages of development. His model systems include Drosophila, mammalian cell lines and mice (in collaboration with Dr. Michael Atchison at University of Pennsylvania).

Selected Publications:

Basu, A, Wilkinson, FH, Colavita, K, Fennelly, C, Atchison, ML. ‘YY1 DNA binding and interaction with YAF2 is essential for Polycomb recruitment’. Nucleic Acids Res. 2014 Feb;42(4):2208-23. PMID:24285299

Pan, X, Papasani, M, Hao, Y, Calamito, M, Wei, F, Quinn, Iii WJ, Basu, A*, Wang, J, Hodawadekar, S, Zaprazna, K, Liu, H, Shi, Y, Allman, D, Cancro, M, Atchison, ML. ‘YY1 Controls Igk Repertoire and B-cell Development, and Localizes with Condensin on the Igk Locus.’  EMBO J. 2013 Apr 17;32(8):1168-82. PMID:23531880

Atchison, ML, Basu, A, Zaprazna, K, Papasani, M. ‘Mechanisms of Yin Yang 1 in oncogenesis: the importance of indirect effects.’ Crit. Rev. Oncog. 2011; 16(3‐4):143‐61. PMID:22248052

Basu, A, Hodawadekar, S, Andrews, O, Knox, A, Pan, X, Wilkinson, FH and Atchison, ML. ‘YY1 PcG Function as a Potential Cancer Therapeutic Target.’ Forum on Immunopathological Diseases and Therapeutics. March 1, 2010; DOI: 10.1615/ForumImmunDisTher.v1.i1-2.30